Volume 34, No 1, Jan 2024

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 34 Issue 1, January 2024: 3-4

RESEARCH HIGHLIGHTS

Caught in the middle: MARCH5 mediates PD-1-induced IL-2R degradation

Xinghao Wang^1,2,3 , Weiping Zou^{1,2,3,4,5,6,*}

¹Department of Surgery, University of Michigan Medical School, Ann Arbor, MI, USA
²Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA
³Graduate Program in Immunology, University of Michigan, Ann Arbor, MI, USA
⁴Graduate Program in Cancer Biology, University of Michigan, Ann Arbor, MI, USA
⁵University of Michigan Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA
⁶Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA
Correspondence: Weiping Zou(wzou@umich.edu)

Blockade of the PD-L1/PD-1 pathway in combination of IL-2 therapy appears to yield synergistic anti-tumor immunity in the treatment of various cancers. In a recent paper published in Cell Research, Liu et al. uncover previously unknown synergistic mechanisms and identify FDA-approved pitavastatin as a potential drug to facilitate such synergy.

https://doi.org/10.1038/s41422-023-00902-3

FULL TEXT | PDF

Browse 161